Wound Healing Research: The Paradigm Shift Editorial Summary Wound healing research is undergoing a transformative shift from single-endpoint clinical studies to patient-centered, multifaceted evaluations. Regulatory changes in both the US and Europe are driving this evolution, demanding more rigorous clinical evidence and broader outcome measures. In the US, the FDA is revising its 2006 guidelines to include additional endpoints beyond complete wound closure, such as Percent Area Reduction, Limb Preservation, and Pain Reduction. Meanwhile, Europe’s Medical Device Regulation (MDR) and Clinical Trials Regulation (CTR) are raising clinical evidence standards and mandating continuous post-market surveillance. Reimbursement challenges further complicate market access. CMS has tightened coverage criteria in the US, recently delisting over 130 wound care products due to insufficient evidence. In Europe, fragmented national healthcare systems require tailored market entry strategies. To navigate this evolving landscape, companies must adopt innovative clinical trial designs, leveraging AI-driven assessments and transatlantic studies. Partnering with specialized wound care CROs will be critical to accelerating regulatory approval and securing reimbursement, ensuring innovative therapies reach patients efficiently.
Introduction
T
Mark D. Cregan Global Clinical Research Institute Copenhagen, Denmark
Morgan Zelen Global Clinical Research Institute Copenhagen, Denmark
Bent von Eitzen Global Clinical Research Institute Copenhagen, Denmark
he Wound Care industry stands at the precipice of a fundamental paradigm shift in how clinical evidence is generated and valued, marking a departure from traditional single-endpoint studies to comprehensive, patient-centric clinical trial designs. This transformation is being catalyzed by evolving regulatory frameworks on both sides of the Atlantic, with the FDA’s consideration of expanding its 2006 guidelines to beyond the conventional endpoint of complete wound closure to embrace a spectrum of clinically relevant outcomes, and simultaneously, Europe’s implementation of the Medical Device Regulation (MDR) and Clinical Trials Regulation (CTR) elevating the standards for clinical evidence generation while creating a more unified approval pathway across EU member states. This synchronous evolution in regulatory requirements, combined with the increased scrutiny of wound care reimbursement in the US and the heterogenous reimbursement landscape in Europe, is driving a commercial need for companies bringing innovative therapies to market, to substantially increase their investment in clinical trials to meet these diverse regulatory and reimbursement needs. To meet the challenge of this coming paradigm shift, there is a growing requirement for specialized clinical research organizations (CROs) that possess sophisticated wound care expertise across trial design, clinical practice, and regulatory/reimbursement landscapes to help expedite the adoption of these innovative products and meet the urgent patient need for these therapies.
Clinical Data and Regulatory Status Updating the FDA Guidelines: Creating opportunities for a Paradigm Shift in Wound Care Research in the USA
Marissa J Carter Strategic Solutions Inc., Bozeman Montana, USA
David G Armstrong
In 2006, the United States Food and Drug Administration (FDA) published comprehensive guidance delineating clinical endpoints for validating the efficacy of novel wound care interventions. The guidance established several key, critical methodological and evaluative parameters for clinical trials: •
University of Southern California, Los Angeles California, USA
•
1
Wound Masterclass - Vol 3 - December 2024
Standardized wound assessment is essential, requiring precise measurements of wound dimensions at baseline and consistent, predetermined intervals throughout the study duration. This approach ensures objective and reproducible evaluation of wound healing progression. The population chosen should optimize the study’s ability to detect